Mésothéliome pleural maligne (MPM) · ligne 2 · Nivolumab en monothérapie (mésothélome 2L, CONFIRM)
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Ligne thérapeutique | 2 |
|---|---|
| Voie | standard |
| Régime lié | REG-NIVO-MONO-MESOTHELIOMA-2L |
| ID | IND-MESOTHELIOMA-2L-NIVO |
|---|---|
| Type | Indication |
| État | reviewed 2026-05-07 | pending_clinical_signoff |
| Maladies | DIS-MESOTHELIOMA |
| Sources | SRC-CONFIRM-FENNELL-2021 SRC-NCCN-NSCLC-2025 |
Notes
CONFIRM (PMID 34090562) is the first phase-3 RCT with OS benefit for 2L MPM. First platinum-based therapy was pemetrexed+cisplatin/carboplatin in most patients. Nivolumab benefit observed in both epithelioid (majority of patients) and non-epithelioid subtypes — distinct from the 1L CheckMate-743 pattern where non-epithelioid derived substantially greater benefit. PD-L1 expression status is NOT required for patient selection; CONFIRM enrolled an unselected population and OS benefit was consistent across PD-L1 subgroups. Active autoimmune disease, prior organ transplantation, and ongoing corticosteroids >10 mg/d prednisone equivalent are clinical contraindications (not KB entity IDs — hard_contraindications remains []). NCCN source note: MPM is managed under a dedicated NCCN Mesothelioma guideline separate from NSCLC. SRC-NCCN-NSCLC-2025 is used as proxy here (same approach as IND-MESOTHELIOMA-1L-NIVO-IPI). A dedicated NCCN mesothelioma source should be added when available.
Utilisé par
Algorithmes
ALGO-MESOTHELIOMA-2L- ALGO-MESOTHELIOMA-2L